IL17A and inflammatory bowel disease: In contrast, compared with the rIL‐22 treatment group, the anti‐IL‐22 antibody that blocks and neutralizes the IL‐22 expression notably elevated IFN‐γ, TNF‐α, and IL‐17 expression and showed more severe IBD symptoms (Figure 5A–F).